CVRx Inc. (CVRX)
CVRx Announces Implementation of New Category I CPT Codes for Barostim Therapy
CVRx Announces Implementation of New Category I CPT Codes for Barostim Therapy
Coeptis Therapeutics S-4 Declared Effective by SEC, Proxy Mailing Begins in Anticipation of the Merger Transaction with Z Squared
Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Continues Progress Toward First-in-Human Trial in Ovarian Cancer
Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer
Hyperfine Announces First Peer-Reviewed Publication Demonstrating Significant Economic Benefits of Using the Swoop® AI-Powered Portable MRI System in Acute Hospital Care
Nuwellis Announces Issuance of New U.S. Patent Supporting Advanced Safety Design for Pediatric Extracorporeal Therapy
Astrana Health, Inc. to Participate in Upcoming Investor Conference
Butterfly Network, Inc. - Butterfly Network to Extend its Proprietary 3D Imaging Capabilities to Butterfly Garden Developers
Johnson & Johnson - Johnson & Johnson unveils new data showing nipocalimab is the first and only investigational FcRn blocker with potential to reduce systemic lupus erythematosus (SLE) activity in a Phase 2 study